Amevive

Amevive Uses, Dosage, Side Effects, Food Interaction and all others data.

Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD.

Interferes with lymphocyte activation by specifically binding to the lymphocyte antigen, CD2, and inhibiting LFA-3/CD2 interaction. Activation of T lymphocytes involving the interaction between LFA-3 on antigen-presenting cells and CD2 on T lymphocytes plays a role in the pathophysiology of chronic plaque psoriasis. Also causes a reduction in subsets of CD2+ T lymphocytes as well as CD4+ and CD8+ T lymphocytes.

Trade Name Amevive
Availability Discontinued
Generic Alefacept
Alefacept Other Names Alefacept
Related Drugs Humira, Otezla, Cosentyx, methotrexate, Enbrel, Remicade, Stelara, cyclosporine, infliximab
Type Intramuscular
Formula C2306H3594N610O694S26
Weight 51801.1 Da
Groups Approved, Investigational, Withdrawn
Therapeutic Class
Manufacturer
Available Country United States
Last Updated: September 19, 2023 at 7:00 am
Amevive
Amevive

Uses

Amevive is a recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis.

As an immunosuppressive drug, Amevive can be used for treatment of moderate to severe chronic plaque psoriasis

How Amevive works

Inhibits T-lymphocyte activation and production by binding to the CD2 lymphocyte antigen.

Toxicity

While it has been found to cross the placenta in monkeys, it is not yet known if it also diffuses into breast milk.

Elimination Route

Bioavailability after IM administration is 63%.

Half Life

~270 hours

Innovators Monograph

You find simplified version here Amevive

*** Taking medicines without doctor's advice can cause long-term problems.
Share